Wang Mingliang

Principal Investigator
Small-Molecule Drug Research Center; Zhongshan Branch of Drug Discovery & Development Institute
 Personal Homepage

CONTACT

wangmingliang@simm.ac.cn

0760-85286866-8516

528400

Room 110, Building C, Sino-Swiss (Euro) Industrial Park, Cuiheng New District, Zhongshan 528400, Guangdong Province, P. R. China

Biography
Dr. Mingliang Wang received his Ph.D. degree in medicinal chemistry from Fudan University in 2017, then he joined the laboratory of Professor Shaomeng Wang as a postdoc at University of Michigan, Ann Arbor. He returned to Shanghai Institute of Materia Medica, Chinese Academy of Science and was appointed to a faculty in 2021. Dr. Wang’s efforts mainly dedicate to the research of medicinal chemistry, his research work focuses on major clinical needs such as tumors and neurodegenerative diseases, design and synthesis of drug-like lead compounds, and lay solid foundation for the research and development of innovative drugs.
Education 
1999.09-2003.06 Bachelor, Wuhan Institute of Technology.
2004.09-2006.06 Master, Major in Medicinal Chemistry, School of Pharmacy, Wuhan University.
2013.09-2017.06 Ph.D., Major in Medicinal Chemistry, School of Pharmacy, Fudan University.
Work Experience 
2017.07-2020.11 Postdoctoral Research Fellow, University of Michigan Ann Arbor, MI. 
2014.09-2015.09 Intern scientist, Medicinal Chemistry, Roche Innovation Center Shanghai.  
2011.05-2013.09 Associated scientist, Medicinal Chemistry, GlaxoSmithKline R&D, Shanghai.
2006.07-2011.04 Organic Synthetic Chemist, Group Leader, Chem. Partner. Ltd, Shanghai. 
Research Directions
1.Discovery and optimization of small-molecule degraders based on proteolysis-targeting chimera (PROTAC) technology.
2.Targeting the key components of the ubiquitin-proteasome system--E3 ubiquitin ligases and deubiquitinating enzymes, design and synthesis of small-molecule modulators of E3 ubiquitin ligases and inhibitors of deubiquitinating enzymes.
3.Targeting the traditional “undruggable targets”, especially protein phosphatase and transcription factors with tumor immunotherapy effects, design and synthesis small-molecule inhibitors\degraders through new strategies for the development of anti-tumor drugs.
 
Grants & Research Projects
 
Achievements
1. Designed and synthesized a new type of allosteric inhibitors targeting SHP2 protein. This type of compounds can effectively inhibit the MAPK signaling pathway and YAP transcription activity, and also show good anti-tumor activity in vivo. First designed and synthesized a new type of degraders targeting SHP2 protein, and also the first reported degraders in PTP family.
2. Designed and synthesized a new type of E3 ubiquitin ligase cereblon (CRBN) ligands. The PROTACs designed and synthesized based on this type of ligands exhibit high-efficiency degradation activity in different targets and also have good drug-like properties.
3. Based on PROTAC technology, designed and synthesized small molecule degraders targeting the estrogen receptor (ERα), and the orally bioavailable estrogen receptor degraders have been initially achieved.
 
morefold
Social Titles
 
morefold
Awards & Honors
 
morefold
Pubilcations
Full Publication List
Selected Publications
1.Mahesh P. Paudyal#, Mingliang Wang (co-first author) #, Juha H. Siitonen, Yimin Hu，Muhammed Yousufuddin, Hong C. Shen*, John R. Falck*, László Kürti*., Intramolecular N-Me and N-H Amino etherification for the Synthesis of N-Unprotected 3-Amino-O-Heterocycles. Org. Biomol. Chem., 2021, 19, 557-560. 
2.Mingliang Wang#, Jianfeng Lu#, Mi Wang, Chao-Yie Yang, Shaomeng Wang*., Discovery of SHP2-D26 as a First, Potent and Effective PROTAC Degrader of SHP2 Protein. J. Med. Chem. 2020, 63, 14, 7510-7528. Highlight as Feature Article and the first PTP family degrader.
3.Jiantao Hu#, Biao Hu#, Mingliang Wang (co-first author) #, Fuming Xu#, Bukeyan Miao#, Chaoyie Yang, Mi Wang, Zhaomin Liu, Daniel Hayes, Krishnapriya Chinnaswamy, James Delproposto, Jeanne Stuckey, Shaomeng Wang*., Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER). J. Med. Chem. , 2019, 62, 3, 1420-1443. 
4.Mingliang Wang, Jilai Han, Xiaojia Si, Yimin Hu, Jidong Zhu* and Xun Sun*., Effective approach to ureas through organocatalyzed one-pot process. Tetrahedron Lett, 2018, 59, 1614-1618. 
5.Jingjing Xie#, Xiaojia Si#, Shoulai Gu, Mingliang Wang, Jian Shen, Haoyan Li, Jian Shen, Dan Li, Yanjia Fang, Cong Liu* and Jidong Zhu*., Allosteric inhibitors of SHP2 with therapeutic potential for cancer treatment. J. Med. Chem., 2017, 60, 10205-10219. 
6.Mingliang Wang, Yanjia Fang, Shoulai Gu, Fangfang Chen, Zhengjiang Zhu, Xun Sun* and Jidong Zhu*., Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine  derivatives as potent and selective CYP17 inhibitors. Eur. J. Med. Chem., 2017, 132, 157-172.
7.Mingliang Wang, Yimin Hu, Zhe Jiang, Hong C. Shen* and Xun Sun*., Divergent Copper-mediated dimerization and hydroxylation of benzamides involving C-H bond functionalization., Org. Biomol. Chem., 2016, 14, 4239-4246.
8.Mingliang Wang, Xixi Liu, Lu Zhou, Jidong Zhu* and Xun Sun*., Fluorination of 2-substituted benzo[b]furans with Selectfluor？., Org. Biomol. Chem., 2015, 13, 3190-3193. 
Representative Patent：
1.Sun Xun, Wang Mingliang, Liu Xixi, Zhou Xinyu., Method for 3-position fluorination of benzofuran ring with 2-position aryl substitute. CN 105837539, 2015. 
2.Sun, Xun, Wang, Mingliang, Zhu, Jidong., Preparing method and medical application of substituted benzothieno[2,3-c]tetrahydropyridine derivative. CN 108264509. 2016.
3.Wang Shaomeng, Hu Jiantao, Hu Biao, Wang Mingliang, Xu Fuming, Miao Bukeyan., Estrogen Receptor Protein Degrader. WO2020142227A1.
 
morefold

Back